Active Studies

The following studies are active. Use the links in the box on the left for information on each of the active studies being conducted by the PASA Consortium. 

AS170014-A1 Colin N Haile, M.D., Ph.D.

Study Type: Preclinical Study
Protocol: Novel Strategies for the Treatment of Opioid Use Disorder and Post-Traumatic Stress Disorder: Anti-Fentanyl Vaccine and Buprenorphine Combination Therapy
Participating Site: Baylor College of Medicine (BCM)


AS170014-A2 Michael T. Bardo, Ph.D.

Study Type: Preclinical Study
Protocol: Preclinical assessment of PT-150 for opioid use disorder and PTSD
Participating Site: University of Kentucky


AS140026-A5 Lori Davis, M.D. and Ismene Petrakis, M.D.

Study Type: Phase II Randomized Controlled Trial (RCT)
Protocol: Kappa Opioid Receptor Antagonism for the Treatment of Alcohol Use Disorder and Comorbid PTSD
Participating Site: Tuscaloosa Research & Education Advancement Corporation (TREAC)/Tuscaloosa VA Medical Center (TVAMC) (Satellite site at Birmingham VA), Connecticut Research & Education Foundation (CREEF) / VA Connecticut Healthcare System (VACT), and Wayne State University, Ann Arbor VA, Detroit VA


AS170014-A6 Christopher Verrico, Ph.D.

Study Type: Phase II Clinical Trial
Protocol: Lofexidine Combined with Buprenorphine for Reducing Symptoms of Post-Traumatic Stress Disorder and Opioid Use Relapse in Veterans
Participating Site: Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)


AS140026-A3c Christopher Verrico, Ph.D. and Dewleen Baker, M.D.

Study Type: Phase I Pharmacokinetic Study
Protocol: Effects of Ethanol (EtOH) on the Pharmacokinetics of PT-150 (Formerly ORG34517)
Participating Site: Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)


AS170014-A5 Marisa Roberto, Ph.D.

Study Type: Preclinical Study
Protocol: Preclinical testing of FKBP5 Inhibitors for alcohol use disorder-PTSD comorbidity
Participating Site: The Scripps Research Institute (TSRI)


AS170014-A7 Ismene Petrakis, M.D. 

Study Type: Phase 1/2 double blinded, placebo-controlled, within-subjects crossover dose exploration design
Protocol:Effect of Sublingual formulation of Dexmedetomidine HCl (BXCL 501) on Ethanol in Healthy Humans and Heavy Drinkers
Participating Site: VA Connecticut Healthcare System